vs
ANI PHARMACEUTICALS INC（ANIP）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Purple Innovation, Inc.的1.8倍（$247.1M vs $140.7M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -2.3%，领先13.4%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 9.1%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $-7.8M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 8.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
ANIP vs PRPL — 直观对比
营收规模更大
ANIP
是对方的1.8倍
$140.7M
营收增速更快
ANIP
高出20.6%
9.1%
净利率更高
ANIP
高出13.4%
-2.3%
自由现金流更多
ANIP
多$36.9M
$-7.8M
两年增速更快
ANIP
近两年复合增速
8.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $140.7M |
| 净利润 | $27.5M | $-3.2M |
| 毛利率 | — | 41.9% |
| 营业利润率 | 14.1% | -1.6% |
| 净利率 | 11.1% | -2.3% |
| 营收同比 | 29.6% | 9.1% |
| 净利润同比 | 367.5% | 62.1% |
| 每股收益（稀释后） | $1.14 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPRPL
| Q4 25 | $247.1M | $140.7M | ||
| Q3 25 | $227.8M | $118.8M | ||
| Q2 25 | $211.4M | $105.1M | ||
| Q1 25 | $197.1M | $104.2M | ||
| Q4 24 | $190.6M | $129.0M | ||
| Q3 24 | $148.3M | $118.6M | ||
| Q2 24 | $138.0M | $120.3M | ||
| Q1 24 | $137.4M | $120.0M |
净利润ANIPPRPL
| Q4 25 | $27.5M | $-3.2M | ||
| Q3 25 | $26.6M | $-11.7M | ||
| Q2 25 | $8.5M | $-17.3M | ||
| Q1 25 | $15.7M | $-19.1M | ||
| Q4 24 | $-10.3M | $-8.5M | ||
| Q3 24 | $-24.2M | $-39.2M | ||
| Q2 24 | $-2.3M | $27.0K | ||
| Q1 24 | $18.2M | $-50.2M |
毛利率ANIPPRPL
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 34.8% |
营业利润率ANIPPRPL
| Q4 25 | 14.1% | -1.6% | ||
| Q3 25 | 15.9% | -10.2% | ||
| Q2 25 | 6.6% | -13.5% | ||
| Q1 25 | 13.3% | -13.9% | ||
| Q4 24 | -2.3% | -6.0% | ||
| Q3 24 | -13.8% | -39.5% | ||
| Q2 24 | 3.7% | -12.1% | ||
| Q1 24 | 14.8% | -19.3% |
净利率ANIPPRPL
| Q4 25 | 11.1% | -2.3% | ||
| Q3 25 | 11.7% | -9.9% | ||
| Q2 25 | 4.0% | -16.5% | ||
| Q1 25 | 8.0% | -18.4% | ||
| Q4 24 | -5.4% | -6.6% | ||
| Q3 24 | -16.3% | -33.1% | ||
| Q2 24 | -1.7% | 0.0% | ||
| Q1 24 | 13.2% | -41.8% |
每股收益（稀释后）ANIPPRPL
| Q4 25 | $1.14 | $0.03 | ||
| Q3 25 | $1.13 | $0.11 | ||
| Q2 25 | $0.36 | $0.16 | ||
| Q1 25 | $0.69 | $0.18 | ||
| Q4 24 | $-0.45 | $0.08 | ||
| Q3 24 | $-1.27 | $0.36 | ||
| Q2 24 | $-0.14 | $0.00 | ||
| Q1 24 | $0.82 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $540.7M | $-29.7M |
| 总资产 | $1.4B | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPPRPL
| Q4 25 | $285.6M | $24.3M | ||
| Q3 25 | $262.6M | $32.4M | ||
| Q2 25 | $217.8M | $34.2M | ||
| Q1 25 | $149.8M | $21.6M | ||
| Q4 24 | $144.9M | $29.0M | ||
| Q3 24 | $145.0M | $23.4M | ||
| Q2 24 | $240.1M | $23.4M | ||
| Q1 24 | $228.6M | $34.5M |
总债务ANIPPRPL
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANIPPRPL
| Q4 25 | $540.7M | $-29.7M | ||
| Q3 25 | $505.8M | $-26.9M | ||
| Q2 25 | $436.8M | $-15.6M | ||
| Q1 25 | $418.6M | $1.3M | ||
| Q4 24 | $403.7M | $20.2M | ||
| Q3 24 | $405.9M | $28.0M | ||
| Q2 24 | $455.8M | $66.4M | ||
| Q1 24 | $452.0M | $65.5M |
总资产ANIPPRPL
| Q4 25 | $1.4B | $296.3M | ||
| Q3 25 | $1.4B | $302.1M | ||
| Q2 25 | $1.3B | $303.8M | ||
| Q1 25 | $1.3B | $293.8M | ||
| Q4 24 | $1.3B | $307.8M | ||
| Q3 24 | $1.3B | $309.3M | ||
| Q2 24 | $920.8M | $362.1M | ||
| Q1 24 | $914.5M | $382.1M |
负债/权益比ANIPPRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-7.8M |
| 自由现金流率自由现金流/营收 | 11.8% | -5.5% |
| 资本支出强度资本支出/营收 | 0.5% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流ANIPPRPL
| Q4 25 | $30.4M | $-5.8M | ||
| Q3 25 | $44.1M | $-968.0K | ||
| Q2 25 | $75.8M | $-4.0M | ||
| Q1 25 | $35.0M | $-23.1M | ||
| Q4 24 | $15.9M | $6.8M | ||
| Q3 24 | $12.5M | $1.1M | ||
| Q2 24 | $17.4M | $-8.9M | ||
| Q1 24 | $18.3M | $-16.8M |
自由现金流ANIPPRPL
| Q4 25 | $29.1M | $-7.8M | ||
| Q3 25 | $38.0M | $-1.8M | ||
| Q2 25 | $71.8M | $-7.0M | ||
| Q1 25 | $32.5M | $-25.3M | ||
| Q4 24 | $13.5M | $5.7M | ||
| Q3 24 | $7.7M | $101.0K | ||
| Q2 24 | $13.0M | $-11.0M | ||
| Q1 24 | $13.7M | $-19.9M |
自由现金流率ANIPPRPL
| Q4 25 | 11.8% | -5.5% | ||
| Q3 25 | 16.7% | -1.5% | ||
| Q2 25 | 34.0% | -6.6% | ||
| Q1 25 | 16.5% | -24.3% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 0.1% | ||
| Q2 24 | 9.4% | -9.2% | ||
| Q1 24 | 10.0% | -16.5% |
资本支出强度ANIPPRPL
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 2.8% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 0.8% | ||
| Q3 24 | 3.2% | 0.9% | ||
| Q2 24 | 3.2% | 1.7% | ||
| Q1 24 | 3.3% | 2.5% |
现金转化率ANIPPRPL
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
